King Acquisition Strategy Will Be Driven By Late-Stage Product Deals
Executive Summary
King Pharmaceuticals is shifting its acquisition strategy to either purchasing or in-licensing late-stage drugs rather than already-marketed products, the company told investors during a quarterly conference call May 6